These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29989668)

  • 21. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.
    Lorenz-Depiereux B; Bastepe M; Benet-Pagès A; Amyere M; Wagenstaller J; Müller-Barth U; Badenhoop K; Kaiser SM; Rittmaster RS; Shlossberg AH; Olivares JL; Loris C; Ramos FJ; Glorieux F; Vikkula M; Jüppner H; Strom TM
    Nat Genet; 2006 Nov; 38(11):1248-50. PubMed ID: 17033625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody.
    Whyte MP
    J Bone Miner Res; 2021 Apr; 36(4):625-626. PubMed ID: 33740291
    [No Abstract]   [Full Text] [Related]  

  • 23. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?
    Lee EK; Martinez MC; Blakely K; Santos KD; Hoang VC; Chow A; Emmenegger U
    Med Hypotheses; 2014 Oct; 83(4):482-7. PubMed ID: 25155552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.
    Fukumoto S; Yamashita T
    Bone; 2007 May; 40(5):1190-5. PubMed ID: 17276744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case 29-2001: oncogenic hypophosphatemic osteomalacia.
    White KE; Waguespack SG; Econs MJ
    N Engl J Med; 2002 Jan; 346(5):381-2. PubMed ID: 11821524
    [No Abstract]   [Full Text] [Related]  

  • 26. NPT2a--the key to phosphate homeostasis.
    Kronenberg HM
    N Engl J Med; 2002 Sep; 347(13):1022-4. PubMed ID: 12324560
    [No Abstract]   [Full Text] [Related]  

  • 27. Tumour-induced osteomalacia.
    Minisola S; Peacock M; Fukumoto S; Cipriani C; Pepe J; Tella SH; Collins MT
    Nat Rev Dis Primers; 2017 Jul; 3():17044. PubMed ID: 28703220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epidemiology of FGF23-related hypophosophatemic diseases].
    Endo I
    Clin Calcium; 2016 Feb; 26(2):223-31. PubMed ID: 26813502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics.
    Clinkenbeard EL; White KE
    Bone; 2017 Sep; 102():31-39. PubMed ID: 28159712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impairment of spatial learning and memory in transgenic mice overexpressing human fibroblast growth factor-23.
    Liu P; Chen L; Bai X; Karaplis A; Miao D; Gu N
    Brain Res; 2011 Sep; 1412():9-17. PubMed ID: 21824606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 23 and its receptors.
    Yu X; White KE
    Ther Apher Dial; 2005 Aug; 9(4):308-12. PubMed ID: 16076372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osmotic demyelination syndrome and leukoencephalopathy in FGF23-related hypophosphatemia: a case report.
    Carandini T; Pozzato M; Scola E; Avignone S; Pietroboni AM
    Neurol Sci; 2021 Jun; 42(6):2549-2551. PubMed ID: 33411198
    [No Abstract]   [Full Text] [Related]  

  • 33. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
    Imel EA; Hui SL; Econs MJ
    J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
    Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
    Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Endocrine control of serum phosphate: from the discoveries of phosphatonins to novel therapies].
    Linglart A; Chaussain C
    Ann Endocrinol (Paris); 2016 Oct; 77 Suppl 1():S36-S42. PubMed ID: 28645356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
    Weber TJ; Liu S; Indridason OS; Quarles LD
    J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule.
    Portale AA; Zhang MY; David V; Martin A; Jiao Y; Gu W; Perwad F
    PLoS One; 2015; 10(11):e0142924. PubMed ID: 26588476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed-1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice.
    Du E; Xiao L; Hurley MM
    J Cell Biochem; 2016 Sep; 117(9):1991-2000. PubMed ID: 26762209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
    Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
    BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.